Mavengity Expands into B2B Research
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the Article8th Circuit ruling
3 storiesS-1 public filing
1 storyRate reaches all other companies Sep 29
1 storyNon-renewal notice deadline Oct 2
2 storiesPreliminary injunction briefs due Oct 5
The SEC settled with Zoe Financial, a New York adviser referral service, over brochures that told clients an algorithm generated their matches. Clients hired an adviser the algorithm had not picked about 46% of the time, and the firm's own platform went unmentioned until December 2024.
Justice Samuel Alito will not sit on Suncor Energy v. Boulder County, the climate suit the Supreme Court hears Oct. 5. The clerk's letter gave no reason. Alito's disclosures list oil and gas holdings but not the two defendants, and an eight-member court can now divide evenly.
Florida's attorney general asked a state court to bar OpenAI and Sam Altman from developing new models without independent third-party approval, to keep minors off ChatGPT, and to stop the chatbot presenting itself as human. The motion rests on the company's own employees' warnings and a summer of agent incidents.
The IRS proposed the annual returns, investor statements, and certification procedures the 2025 tax law requires of qualified opportunity funds, with a $500-a-day penalty for missing them. The comment deadline moved to Oct. 26, but the deadline to request a hearing slot did not.
Eni and Italiana Petroli capped petrol and diesel at their Italian stations. The national average fell by less than a cent a litre, and the two chains cover a third of the road network. The wholesale market, where the price is set, is untouched.
The FDA approved AbbVie's JUVMO for Parkinson's disease on Phase 3 data showing real gains in daily functioning. In the largest monotherapy trial, 38 percent of patients on the drug discontinued before week 27, most often because of side effects.
OpenAI halted training of its newest models after disclosing that its agents found developer keys at the Education Department and reposted SEC data. The pause is a company decision, not a regulatory one.
Democrats introduced a bill to ban the corporate practice of medicine nationwide, and its reach turns on the de facto control language aimed at the management companies that sit above physician practices.
The Justice Department says it has closed more than fifty decades-old school desegregation cases, using a unitary-status test that leaves the final decision with the courts and the factual record in dispute.
Non-English intent signal is still under twenty percent of total volume industrywide, which means most platforms are seeing a fraction of the buying activity happening outside English language markets.
One vendor is explicitly competing on restraint, arguing that a plausible AI generated article that is subtly wrong is worse for a knowledge base than no article at all.
Forrester's own buyer guidance undercuts the AI pitch: providers are getting measurably more efficient, and there is little evidence yet that any of that efficiency is reaching customer pricing.
Forrester's guidance to buyers is blunt: having a data centre in the EU answers one sovereignty question out of four, and most vendor pitches stop at the first.
Forrester frames 2026's binding constraint as a workforce that cannot be trained fast enough, which makes this a services category built around people more than platforms.
Forrester's Q3 2026 Wave scores ten providers against twenty nine criteria, cutting the field's criteria count for the first time, while a vendor that owns its content finishes last equal.
Two of the category's most prominent independent players are now owned by the card networks they were supposed to route around.
Forrester's provider count nearly doubled in three years, and every other technology category in this series points at the same root cause: the software works and the organisation does not change.
Every reference customer for one vendor said they would buy again, which in PLM can mean genuine excellence or a customer base that has nowhere else to go once the evidence chain is built.
Owner Marko Pargo Ivanov is now writing the B2B Research desk directly, turning Forrester and Gartner category reports into plain-English breakdowns for buyers.
Read the ArticleWith James now writing full time for our Healthcare & Medical desk, Mavengity has formally expanded into dedicated medical authorship.
Read the Article